Meridian Bioscience Supports Diagnostic Companies in Fighting Coronavirus Pandemic by Providing Zero Cost Proprietary Technology for Evaluation
March 16, 2020 11:51 ET
|
Meridian Bioscience Inc.
CINCINNATI, March 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its increased commitment to the global fight against COVID-19 by making available zero cost...
Meridian Bioscience Announces FDA-Clearance for New Curian™ Analyzer and the Curian™ HpSA® Assay
March 16, 2020 08:00 ET
|
Meridian Bioscience Inc.
CINCINNATI, March 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of immunoassay, molecular, and blood chemistry diagnostic testing solutions, today announced that...
Meridian’s Novel Air-Dryable qPCR Mix Decreases Costs and Simplifies Workflows for Molecular Test Manufacturers
February 26, 2020 08:00 ET
|
Meridian Bioscience Inc.
CINCINNATI, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), following the extremely successful launch of the Lyo-Ready qPCR mixes, is proud to introduce today its...
Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform
February 19, 2020 09:15 ET
|
Meridian Bioscience Inc.; Exalenz Bioscience
CINCINNATI and MODIIN, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies have entered...
Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results and Reaffirms 2020 Guidance
February 07, 2020 07:30 ET
|
Meridian Bioscience Inc.
CINCINNATI, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2019. First Quarter Fiscal 2020...
Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak
January 27, 2020 09:17 ET
|
Meridian Bioscience Inc.
CINCINNATI, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named...
Meridian เปิดตัวพอลิเมอเรสความแม่นยำสูงแบบใหม่เพื่อให้การเพิ่มจำนวนที่แข็งแกร่งสำหรับประโยชน์ในงานวิเคราะห์ NGS และ PCR
January 23, 2020 16:46 ET
|
Meridian Bioscience Inc.
ซินซินนาติ, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) ได้ประกาศในวันนี้ถึงการเปิดตัว High-Specificity Pfu HS Mix ซึ่งไม่เพียงแต่ให้การเพิ่มปริมาณที่มีความแม่นยำสูง...
Meridian Melancarkan Polimerase Fideliti Tinggi Baharu untuk Menawarkan Penguatan Kukuh untuk Aplikasi NGS dan PCR
January 23, 2020 16:46 ET
|
Meridian Bioscience Inc.
CINCINNATI, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) hari ini mengumumkan Campuran HS Pfu Spesifikasi Tinggi yang bukan sahaja menyediakan penguatan fideliti...
메리디안, NGS와 PCR 애플리케이션에 강력한 증폭 능력을 제공하는 정확성 높은 중합효소 공개
January 23, 2020 16:46 ET
|
Meridian Bioscience Inc.
신시내티, Jan. 24, 2020 (GLOBE NEWSWIRE) -- 메리디안 바이오사이언스(Meridian Bioscience, Inc.)(NASDAQ: VIVO)는 정확성 높은 증폭 능력과 함께 동반진단(CDx) 및 임상 테스트용 증폭 능력을 제공하는 High-Specificity Pfu HS Mix를 공개했다. 정확성 높은 증폭 능력은...
Meridian 推出一種新的高保真聚合酶，可為 NGS 和 PCR 應用提供可靠的擴增
January 23, 2020 16:46 ET
|
Meridian Bioscience Inc.
辛辛那提, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) 今天宣佈推出高特異性 Pfu HS Mix，不但可提供高保真擴增，而且提供具有市場領先地位的擴增，用於伴隨診斷 (CDx) 和臨床測試。 高保真擴增對於結果取決於正確 DNA 序列的應用至關重要，例如下一代測序...